Commercial milestone payments.

No definition available.

Name:	nmra_CommercialMilestonePayments
Namespace Prefix:	nmra_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Deferred funding current.

+ References

No definition available.

+ Details

Name:	nmra_DeferredFundingCurrent
Namespace Prefix:	nmra_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Development and regulatory milestone payments.

+ References

No definition available.

+ Details

Name:	nmra_DevelopmentAndRegulatoryMilestonePayments
Namespace Prefix:	nmra_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Fund received upon completion of certain development milestone.

+ References

No definition available.

+ Details

Name:	nmra_FundReceivedUponCompletionOfCertainDevelopmentMilestone
Namespace Prefix:	nmra_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Funds provided for pre-clinical research and development activities.

+ References

No definition available.

+ Details

Name:	nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities
Namespace Prefix:	nmra_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Funds provided for pre-clinical research and development activities in tranches.

+ References

No definition available.

+ Details

Name:	nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivitiesInTranches
Namespace Prefix:	nmra_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Maximum repayment amount agreed to pay.

+ References

No definition available.

+ Details

Name:	nmra_MaximumRepaymentAmountAgreedToPay
Namespace Prefix:	nmra_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Maximum repayment obligation.

+ References

No definition available.

+ Details

Name:	nmra_MaximumRepaymentObligation
Namespace Prefix:	nmra_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone Payments

+ References

No definition available.

+ Details

Name:	nmra_MilestonePayments
Namespace Prefix:	nmra_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestones achieved.

+ References

No definition available.

+ Details

Name:	nmra_MilestonesAchieved
Namespace Prefix:	nmra_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Payments for execution of agreement.

+ References

No definition available.

+ Details

Name:	nmra_PaymentsForExecutionOfAgreement
Namespace Prefix:	nmra_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(24))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=nmra_TwoThousandAndFifteenTsriLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nmra_GCaseProgramAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nmra_ParkinsonsResearchVenturesFundingAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Strategic License and Research and Collaboration Agreements - Additional Information (Details) £ in Millions	1 Months Ended								3 Months Ended		6 Months Ended
	May 31, 2026 USD ($)	Nov. 30, 2025 USD ($)	Oct. 31, 2025 USD ($)	Jan. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Mar. 31, 2024 USD ($)	Oct. 31, 2023 USD ($)	Nov. 30, 2015 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2026 GBP (£)	Jun. 30, 2025 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expenses									$ 29,283,000	$ 38,724,000	$ 67,881,000		$ 90,875,000
Fund received upon completion of certain development milestone				$ 1,500,000
2015 TSRI License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones achieved									0		0
Milestone Payments							$ 300,000
Accrued Royalties									0		0
2015 TSRI License Agreement \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Development and regulatory milestone payments								$ 1,500,000
Commercial milestone payments								$ 3,500,000
GCase Program Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expenses									900,000	100,000	1,300,000		100,000
Deferred funding									2,900,000		2,900,000
Payments for execution of agreement	$ 1,600,000	$ 1,700,000
Maximum Repayment Obligation			$ 6,600,000
GCase Program Agreement \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Funds provided for preclinical research and development activities			$ 3,300,000
Parkinson's Research Ventures Funding Agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expenses									0	$ 1,100,000	100,000		$ 1,200,000
Deferred funding									$ 100,000		100,000
Funds provided for preclinical research and development activities in tranches					$ 400,000
Funds provided for preclinical research and development activities					1,700,000
Payments for execution of agreement						$ 1,100,000					1,300,000
Maximum Repayment Obligation					$ 3,300,000
Maximum repayment amount agreed to pay. \| £												£ 8.4
Parkinson's Research Ventures Funding Agreements \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Funds provided for preclinical research and development activities											$ 2,600,000